Drug Profile
ASP 6282
Alternative Names: ASP6282Latest Information Update: 07 Feb 2018
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bladder dysfunction
Most Recent Events
- 07 Feb 2018 Discontinued - Phase-I for Bladder dysfunction (In volunteers) in United Kingdom and Germany (PO) (Astellas Pharma pipeline, February 2018)
- 01 May 2016 Astellas Pharma completes a phase I trial in in Bladder dysfunction (In volunteers) in Germany and United Kingdom (NCT02420782)
- 01 May 2015 Phase-I clinical trials in Bladder dysfunction (In volunteers) in United Kingdom, Germany (PO) (NCT02420782)